Role of micro-RNAs in drug resistance of multiple myeloma
Metrics: PDF 1050 views | HTML 1389 views | ?
Jahangir Abdi1,2, Hou Jian3 and Hong Chang1,2,4
1 Division of Molecular and Cellular Biology, Toronto General Research Institute, Toronto, Ontario, Canada
2 Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada
3 Department of Hematology, Shanghai Chang Zheng Hospital, Shanghai, China
4 Department of Laboratory Hematology and Medical Oncology, University Health Network, Toronto, Ontario, Canada
Hong Chang, email:
Keywords: miRNA, drug resistance, multiple myeloma
Received: May 18, 2016 Accepted: July 19, 2016 Published: August 02, 2016
While novel therapeutic approaches have profoundly improved survival of multiple myeloma (MM) patients, drug resistance and treatment refractoriness still persists. This obstacle highly demands thorough investigation into the root and underlying molecular mechanisms to develop more effective strategies. The advent of micro-RNAs (miRNAs) in the study of cancer biology and pathogenesis in recent years has revolutionized therapy in this field and particularly opened new windows to further understanding of tumor drug resistance. However; in spite of the fact that miRNAs involvement in MM pathogenesis and progression has been substantially evidenced, miRNA investigation in MM drug resistance is still in its infancy. Our knowledge of the potential role of miRNAs in MM drug resistance comes from few recent reports confirming that some miRNAs including miR-137/197, miR-21 and miR-221/222 could negatively modulate drug sensitivity of MM cells. Further continuous researches are required to exploit miRNAs to elucidate the critical mechanisms controlling drug resistance in MM. In this review, we will highlight the most recent observations on the role of miRNAs in MM drug resistance. Moreover, approaches and insights into clinical application of miRNAs to overcome MM drug resistance will be discussed.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.